LoginRegister
    Violation of Market Norms: SEBI imposes Rs 1.15 crore fine on Pharma CompanyViolation of Market Norms: SEBI imposes Rs 1.15 crore fine on Pharma Company
    Biocon gets 4 observations, Complete Response Letter from USFDA for Insulin GlargineBiocon gets 4 observations, Complete Response Letter from USFDA for Insulin Glargine
    5 pc GDP should act as wake-up call for Government to act more: Kiran Mazumdar Shaw5 pc GDP should act as wake-up call for Government to act more: Kiran Mazumdar Shaw
    Sandoz recalls Losartan Potassium, Ezetimibe drug bottles in US over packaging issueSandoz recalls Losartan Potassium, Ezetimibe drug bottles in US over packaging issue
    USFDA expands investigation on generic drug impurities in USUSFDA expands investigation on generic drug impurities in US
    AstraZeneca lupus drug Anifrolumab shows encouraging sign in final stageAstraZeneca lupus drug Anifrolumab shows encouraging sign in final stage
    Hospitals permitted to add trade margin on orthopaedic knee implants: NPPA ClarificationHospitals permitted to add trade margin on orthopaedic knee implants: NPPA Clarification
    AIOCD threatens to Boycott CIPLA if it enters into E-Pharmacy BusinessAIOCD threatens to Boycott CIPLA if it enters into E-Pharmacy Business
    GSK Pharma sells 60 acres land in Thane to Oberoi Realty for Rs 890 croreGSK Pharma sells 60 acres land in Thane to Oberoi Realty for Rs 890 crore
    Alkem Labs gets 2 USFDA observations for Daman facilityAlkem Labs gets 2 USFDA observations for Daman facility
    Aurobindo Pharma, Shanghai LongJin sign deal to form JV in ChinaAurobindo Pharma, Shanghai LongJin sign deal to form JV in China
    Mylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug AlimtaMylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug Alimta
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X